Please login to the form below

Not currently logged in
Email:
Password:

Study suggests SSRI risk for older people

Cohort study suggests new generation antidepressants, SSRIs, may carry greater risks than alternatives for older people

A study has suggested that the new generation of antidepressants, selective serotonin reuptake inhibitors (SSRIs), may have an increased risk for older people.

The study, published in the British Medical Journal (BMJ). indicated that SSRIs are associated with increased levels of several severe adverse outcomes in older people compared to alternative antidepressants such as tricyclics (TCAs).

The cohort investigation, conducted by the University of Nottingham and East Anglia, researched the association between antidepressant treatment and potential life threatening outcomes in patients aged 65 and over.

Overall it was found that SSRIs were associated with an increased risk of all cause mortality, stroke, falls, fracture, epilepsy or seizures and hyponatraemia.

Individual drugs such as trazodone (marketed as Desyrel by Bristol-Myers Squibb), mirtazapine (marketed as Remeron by Organon Pharmaceuticals) and venlafaxine (marketed as Effexor by Pfizer) were associated with the highest risks for several negative outcomes.

Although further research is needed to confirm these findings, the authors state that the risks and benefits of different antidepressants should be carefully evaluated when they are prescribed to older patients.

3rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics